FY2025 Earnings Estimate for PTCT Issued By Leerink Partnrs

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Equities research analysts at Leerink Partnrs lowered their FY2025 earnings per share (EPS) estimates for PTC Therapeutics in a research note issued to investors on Tuesday, November 4th. Leerink Partnrs analyst J. Schwartz now anticipates that the biopharmaceutical company will post earnings of $5.52 per share for the year, down from their prior forecast of $8.33. The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.52) per share. Leerink Partnrs also issued estimates for PTC Therapeutics’ Q4 2025 earnings at ($0.97) EPS, Q1 2026 earnings at ($1.03) EPS, Q2 2026 earnings at ($0.92) EPS, Q3 2026 earnings at ($0.29) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($1.66) EPS and FY2027 earnings at ($0.89) EPS.

Several other research firms have also issued reports on PTCT. Wells Fargo & Company lifted their price target on shares of PTC Therapeutics from $73.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday. Barclays raised their price objective on PTC Therapeutics from $46.00 to $68.00 and gave the stock an “equal weight” rating in a research note on Wednesday. Jefferies Financial Group lifted their target price on PTC Therapeutics from $63.00 to $77.00 and gave the stock a “buy” rating in a report on Tuesday, October 28th. Robert W. Baird set a $70.00 price target on PTC Therapeutics in a research report on Friday, August 8th. Finally, UBS Group lifted their price target on PTC Therapeutics from $71.00 to $80.00 and gave the stock a “buy” rating in a research note on Tuesday, July 29th. Ten equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $75.40.

PTC Therapeutics Price Performance

NASDAQ PTCT opened at $72.59 on Friday. PTC Therapeutics has a 12 month low of $35.95 and a 12 month high of $73.98. The company has a market capitalization of $5.77 billion, a P/E ratio of 10.41 and a beta of 0.60. The company’s 50 day simple moving average is $62.86 and its 200 day simple moving average is $53.44.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.19) by $1.39. The company had revenue of $211.01 million during the quarter, compared to the consensus estimate of $177.42 million. PTC Therapeutics had a net margin of 35.65% and a negative return on equity of 106.31%. PTC Therapeutics’s revenue was up 7.2% on a year-over-year basis. During the same period in the prior year, the company earned ($1.39) EPS. PTC Therapeutics has set its FY 2025 guidance at EPS.

Insider Buying and Selling at PTC Therapeutics

In other PTC Therapeutics news, insider Eric Pauwels sold 39,850 shares of the firm’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $56.92, for a total transaction of $2,268,262.00. Following the completion of the sale, the insider directly owned 72,912 shares in the company, valued at approximately $4,150,151.04. This trade represents a 35.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Neil Gregory Almstead sold 55,000 shares of PTC Therapeutics stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $66.05, for a total value of $3,632,750.00. Following the transaction, the insider directly owned 100,625 shares in the company, valued at approximately $6,646,281.25. This trade represents a 35.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 254,662 shares of company stock valued at $16,000,821 in the last ninety days. Company insiders own 5.50% of the company’s stock.

Institutional Trading of PTC Therapeutics

Institutional investors have recently made changes to their positions in the stock. Smartleaf Asset Management LLC grew its position in PTC Therapeutics by 101.3% during the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 236 shares in the last quarter. Quantbot Technologies LP boosted its stake in shares of PTC Therapeutics by 545.5% during the 1st quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 551 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of PTC Therapeutics by 84.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 320 shares during the period. GAMMA Investing LLC grew its holdings in shares of PTC Therapeutics by 86.3% during the 1st quarter. GAMMA Investing LLC now owns 952 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 441 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in shares of PTC Therapeutics by 247.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,143 shares of the biopharmaceutical company’s stock worth $56,000 after acquiring an additional 814 shares during the last quarter.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.